IL33 and allergic disease: We have previously reported the restoration of the epithelial barrier function by inhibiting the expression of key promoters of allergy (thymic stromal lymphopoietin [TSLP] and interleukin 33 [IL-33]), which contribute to the Th2 immune response observed in early AD9.